Emapalumab-lzsg

(Gamifant®)

Gamifant®

Drug updated on 12/19/2023

Dosage FormInjection: (intravenous; 10 mg/2 mL, 50 mg/10 mL, 100 mg/20 mL)
Drug ClassInterferon gamma blocking antibodies
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Gamifant (emapalumab-lzsg) Prescribing Information.2022Sobi Inc., Waltham, MA

Randomized Controlled Trials

Document TitleSex DistributionYearSource
Emapalumab in children with primary hemophagocytic lymphohistiocytosis.
34Subjects
F: 53%
M: 47%
2020The New England Journal of Medicine

Sex Distribution:

F:53%
M:47%
34Subjects

Year:

2020

Source:The New England Journal of Medicine

Clinical Practice Guidelines

Document TitleYearSource
Emapalumab-lzsg (Gamifant). 2023https://www.aetna.com/cpb/medical/data/900_999/0948.html